Welcome to our dedicated page for GALERA THERAPEUTICS news (Ticker: GRTX), a resource for investors and traders seeking the latest updates and insights on GALERA THERAPEUTICS stock.
Galera Therapeutics, Inc. (Nasdaq: GRTX), headquartered in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to transforming radiotherapy in cancer through innovative therapeutics. The company is currently focused on the development and commercialization of two primary product candidates: avasopasem manganese (avasopasem) and rucosopasem manganese (rucosopasem).
Avasopasem, a selective dismutase mimetic, has been developed to reduce radiation-induced severe oral mucositis (SOM) in patients with head and neck cancer. Despite receiving Fast Track and Breakthrough Therapy designations from the FDA, the company's New Drug Application (NDA) for avasopasem was met with a Complete Response Letter, requiring additional clinical trials for resubmission.
Rucosopasem aims to enhance the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Though rucosopasem has been granted orphan drug designation by the FDA, the company recently made the difficult decision to halt the Phase 2b GRECO-2 trial and the Phase 1/2 GRECO-1 trial due to a futility analysis of the GRECO-2 trial.
Following these setbacks, Galera has taken decisive steps to extend its cash runway, including workforce reductions and shifting focus towards strategic alternatives such as partnerships, mergers, and asset sales. As of the latest financial updates, the company estimates its balance of cash, cash equivalents, and marketable securities to support operations into the second quarter of 2024. Galera is actively evaluating these strategic options to maximize shareholder value while continuing its mission to improve cancer treatment outcomes.
For more information, visit the Investors page of Galera’s website.
Galera Therapeutics (GRTX) has released interim data from its pilot Phase 1/2 clinical trial of avasopasem manganese (GC4419) combined with stereotactic body radiation therapy (SBRT) for locally advanced pancreatic cancer. The results show that the median overall survival for the treatment group has not yet been reached, compared to 40.4 weeks for the placebo group (HR=0.3; p=0.046). The trial also indicated better progression-free survival and locoregional control. Full data from 42 patients will be presented at the ASTRO meeting on October 27.
Galera Therapeutics announced the first patient dosing in the Phase 1/2 GRECO-1 clinical trial of GC4711 in combination with stereotactic body radiation therapy (SBRT) for patients with non-small cell lung cancer (NSCLC). GC4711 is designed to enhance the efficacy of SBRT while protecting normal lung tissue. The trial, supported by an NIH SBIR grant, aims to assess tumor outcomes and lung injury in up to 66 NSCLC patients. This builds on prior studies indicating increased anti-cancer efficacy when combined with SBRT.
Galera Therapeutics (Nasdaq: GRTX) announced a virtual Key Opinion Leader event on locally advanced pancreatic cancer scheduled for October 2, 2020, at 11 a.m. EDT. Dr. Sarah Hoffe from Moffitt Cancer Center will discuss patient management and stereotactic body radiation therapy. The event will be accessible via Galera's Investors page, with an interactive Q&A session. A recorded version will be available for 60 days post-event. Galera is focused on developing therapeutics for cancer treatment, including its lead candidate, avasopasem manganese, designed to reduce radiation-induced severe oral mucositis.
Galera Therapeutics (Nasdaq: GRTX) has initiated a pilot Phase 2 clinical trial for its lead candidate GC4419, aimed at improving 28-day mortality in critically ill COVID-19 patients. The trial, enrolling up to 50 hospitalized adults, is randomized and placebo-controlled, assessing the safety and efficacy of GC4419. This investigation aligns with Galera's ongoing efforts to evaluate GC4419's potential in treating radiation toxicities and enhancing cancer therapy. GC4419 is recognized for its ability to mitigate superoxide-induced tissue damage, crucial in severe COVID-19 cases.
Galera Therapeutics (Nasdaq: GRTX) announced that its CEO, Mel Sorensen, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 1:40 p.m. EDT. A live webcast can be accessed via Galera's Investors page, with an archived version available for 30 days post-event. Galera focuses on developing novel therapeutics to enhance cancer radiotherapy, with its flagship product, avasopasem manganese (GC4419), currently undergoing multiple clinical trials.
Galera Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: GRTX), announced that CEO Mel Sorensen will participate in a fireside chat at the 2020 BTIG Virtual Biotechnology Conference on August 10, 2020, at 9:30 a.m. EDT. A live webcast will be available on the company’s Investors page, and an archived version will be posted for 30 days post-event. Galera focuses on developing therapeutics to transform cancer radiotherapy, with lead candidate avasopasem manganese aimed at reducing radiation-induced severe oral mucositis in head and neck cancer patients.
Galera Therapeutics (Nasdaq: GRTX) has completed patient enrollment in its Phase 1b/2a clinical trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy (SBRT) for locally advanced pancreatic cancer (LAPC). This pilot trial aims to evaluate safety, overall response rate, and progression-free survival compared to a placebo. Positive preclinical results have been noted for GC4419, which acts as a superoxide dismutase mimetic to protect healthy tissues during radiation. Topline data is expected in the second half of 2020, highlighting the urgency for better treatment options for pancreatic cancer.
Galera Therapeutics (Nasdaq: GRTX) will host a virtual Key Opinion Leader event on cisplatin-induced chronic kidney disease on May 22, 2020, from 10 a.m. to 11 a.m. EDT. The event will address clinical challenges related to nephrotoxicity in patients undergoing platinum-based chemotherapy for head and neck cancer. A discussion will summarize preliminary findings from a retrospective analysis of Phase 2b trial data and explore the potential role of avasopasem manganese (GC4419). A live audio webcast will be available on Galera's investors website, with an archived version accessible for 60 days.
Galera Therapeutics (GRTX) announced positive findings from a retrospective analysis of Phase 2b trial data for avasopasem manganese (GC4419), a drug aimed at reducing radiation-induced toxicities in cancer treatment. The trial showed a significant reduction in chronic kidney disease incidences among patients who received cisplatin and avasopasem. These results will be presented at the ASCO 2020 Virtual Scientific Program. Additionally, ongoing Phase 3 ROMAN and Phase 1b/2a trials are set to yield further data in the second half of 2020 and 2021, respectively.
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that CEO Mel Sorensen, M.D. will present virtually at the BofA Securities 2020 Health Care Conference on May 12, 2020, at 9:40 a.m. EDT. The presentation will be accessible via a live audio webcast on Galera's Investors page, with an archived version available for 30 days post-event. Galera focuses on developing novel therapeutics to transform cancer radiotherapy, including their lead candidate, avasopasem manganese, currently in Phase 3 trials for reducing radiation-induced severe oral mucositis.
FAQ
What is the current stock price of GALERA THERAPEUTICS (GRTX)?
What is the market cap of GALERA THERAPEUTICS (GRTX)?
What is Galera Therapeutics' primary focus?
What are the main product candidates of Galera Therapeutics?
What is avasopasem developed for?
Why did the FDA issue a Complete Response Letter for avasopasem?
What designation has the FDA granted to avasopasem?
What is rucosopasem developed to do?
Why were the GRECO trials for rucosopasem halted?
What strategic steps is Galera Therapeutics taking following recent setbacks?
What is the current financial outlook for Galera Therapeutics?
Where is Galera Therapeutics headquartered?
